Skip to main content

Epizyme, Inc. (EPZM)

NASDAQ: EPZM · Delayed Price · USD
5.30
-0.03 (-0.56%)
After-hours:Sep 24, 2021 6:20 PM EDT
5.33
-0.14 (-2.56%)
At close: Sep 24, 4:00 PM
Market Cap554.20M
Revenue (ttm)32.58M
Net Income (ttm)-256.94M
Shares Out102.05M
EPS (ttm)-2.53
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume478,361
Open5.46
Previous Close5.47
Day's Range5.30 - 5.50
52-Week Range4.72 - 14.30
Beta1.17
AnalystsBuy
Price Target11.14 (+109.0%)
Est. Earnings DateNov 4, 2021

About EPZM

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with...

IndustryBiotechnology
IPO DateMay 31, 2013
CEORobert Bazemore
Employees304
Stock ExchangeNASDAQ
Ticker SymbolEPZM
Full Company Profile

Financial Performance

In 2020, Epizyme's revenue was $15.76 million, a decrease of -33.77% compared to the previous year's $23.80 million. Losses were -$231.69 million, 36.1% more than in 2019.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for Epizyme stock is "Buy." The 12-month stock price forecast is 11.14, which is an increase of 109.01% from the latest price.

Price Target
$11.14
(109.01% upside)
Analyst Consensus: Buy

News

Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that...

1 week ago - Business Wire

Why Is Epizyme (EPZM) Up 3.8% Since Last Earnings Report?

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

2 weeks ago - Zacks Investment Research

Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the C...

1 month ago - Business Wire

Epizyme's (EPZM) Q2 Earnings Miss, Revenues Beat Estimates

Epizyme (EPZM) reports wider-than-expected loss for the second quarter of 2021 despite its revenues beating estimates. As a result, stock price declines.

1 month ago - Zacks Investment Research

Why Epizyme Is Getting Crushed Today

It's uncomfortable when a company delivers an earnings miss and announces a CEO's departure on the same day.

1 month ago - The Motley Fool

Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of -5.00% and 48.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Recap: Epizyme Q2 Earnings

Shares of Epizyme (NASDAQ:EPZM) moved higher by 13.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 8.62% year over year to ($0.63), which m...

1 month ago - Benzinga

Epizyme Announces CEO Succession

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies today announced its C...

1 month ago - Business Wire

Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today reported its second ...

1 month ago - Business Wire

Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater China

Epizyme Inc (NASDAQ: EPZM) and HUTCHMED (China) Limited (NASDAQ: HCM) have collaborated to research, develop, manufacture, and commercialize Tazverik (tazemetostat) in Greater China, including mainland ...

Other symbols:HCM
1 month ago - Benzinga

Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greate...

CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J.--(BUSINESS WIRE)--Epizyme, Inc. (“Epizyme”) (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and del...

1 month ago - Business Wire

Epizyme Announces Date of Second Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that mana...

1 month ago - Business Wire

Analysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out for

Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Why Epizyme Stock Is Falling This Week

The cancer drug developer's CFO will soon exit the company.

2 months ago - The Motley Fool

Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today launched the EZH2Now...

Other symbols:DGX
3 months ago - Business Wire

Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models

Epizyme Inc (NASDAQ: EPZM) has reported positive data from mouse studies for potential first-in-class therapy, EPZ-719, that targets the enzyme SETD2. The chromosomal abnormality is responsible for abou...

3 months ago - Benzinga

Epizyme to Participate in Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robe...

3 months ago - Business Wire

Epizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Confe...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that...

4 months ago - Business Wire

Etsy, Monster Beverage, Nokia and More Friday Afternoon Analyst Calls

With the trading day about halfway over, markets pushed higher into the weekend. The Nasdaq was the biggest winner on the day, with the index up over 1.3%.

4 months ago - 24/7 Wall Street

Epizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates

Epizyme (EPZM) reports wider-than-expected loss in the first quarter of 2021 despite its revenues beating estimates.

4 months ago - Zacks Investment Research

Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of -23.21% and 7.71%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business an...

4 months ago - Business Wire

Epizyme Announces Date of First Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that mana...

4 months ago - Business Wire

5 Small-Cap Biotech Stocks Trading Under $10 With Massive Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other symbols:AFMDCMRXSEELWVE
5 months ago - 24/7 Wall Street

Epizyme (EPZM) Down 22.9% Since Last Earnings Report: Can It Rebound?

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research